nis793
mAbexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Apr 25, 2017 (NCT02947165)
Timeline
Indications
Mechanism of action
- Transforming growth factor beta-1INHIBITOR
TGFB1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- nis793
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05546411 | Phase 2 | Mar 31, 2023 | Harvard University, Novartis |
| NCT05417386 | Phase 1 | Aug 9, 2022 | Harvard University, Novartis |
| NCT04952753 | Phase 2 | Nov 15, 2021 | Novartis |
| NCT04935359 | Phase 3 | Sep 30, 2021 | Novartis |
| NCT04810611 | Phase 1 | Jun 18, 2021 | Novartis |
| NCT04390763 | Phase 2 | Aug 5, 2020 | Novartis |
| NCT04283526 | Phase 1 | Apr 30, 2020 | Novartis |
| NCT02947165 | Phase 1 | Apr 25, 2017 | Novartis |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 8 | 6 | 3 | 2017 |
| Harvard University | Academic/Hospital | 2 | 2 | 2 | 2022 |
2 organizations
Page 1 / 1